文献速递淋巴瘤

套细胞淋巴瘤一线BR后利妥昔单抗维持治疗获益

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

该多中心回顾性研究纳入911例接受一线苯达莫司汀-利妥昔单抗(BR)治疗的套细胞淋巴瘤(MCL)患者,703例在BR后3个月landmark时达客观缓解且无进展证据,其中394例(56%)接受利妥昔单抗维持、309例(44%)未接受。Landmark分析显示维持治疗与更优的无事件生存(EFS;中位49.9 vs 29.7个月;P< .001)和总生存(OS;中位109.5 vs 74.2个月;P< .001)相关。

要点

  • 一线BR后利妥昔单抗维持与EFS和OS显著改善相关。
  • 完全缓解亚组(n=590)中维持治疗的EFS和OS差异均显著。
  • 部分缓解亚组因样本量小,分析受限。

核心结论

  • 一线BR后利妥昔单抗维持治疗与MCL患者EFS和OS改善相关。

研究设计与样本

  • 美国与加拿大27个学术中心开展的大规模回顾性研究。
  • 2010至2020年间911例患者接受一线BR治疗,703例在BR后3个月landmark时达客观缓解且无进展证据。

主要发现

  • 394例(56%)接受利妥昔单抗维持,309例(44%)未接受,两组基线特征基本相似。
  • Landmark分析中,维持组中位EFS为49.9个月 vs 29.7个月(P< .001),中位OS为109.5个月 vs 74.2个月(P< .001)。
  • EFS和OS获益在大多数亚组中均观察到。
  • 完全缓解亚组(n=590)中位EFS为62.7 vs 31.1个月(P< .001),中位OS为136.1 vs 75.3个月(P< .001)。
  • 部分缓解亚组分析因样本量小受限。

临床怎么用

  • 结果为MCL一线BR后利妥昔单抗维持治疗的生存获益提供额外证据,支持其用于临床试验设计和常规实践。

局限性

  • 为回顾性研究设计。
  • 部分缓解亚组分析因样本量小受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Canadian academic centers to examine the benefit of rituximab maintenance after BR. A total of 911 patients received 1L BR between 2010 and 2020, and 703 had an objective response and no evidence of disease progression at the 3-month post-BR landmark. Among those, 394 (56%) received rituximab maintenance and 309 (44%) did not, with largely similar baseline patient and disease characteristics. In the landmark analysis, rituximab maintenance was associated with improved event-free survival (EFS; median, 49.9 vs 29.7 months; P< .001) as well as overall survival (OS; median, 109.5 vs 74.2 months; P< .001). The EFS and OS benefits were observed across most of the subgroups. EFS and OS differences were statistically significant in those who achieved a complete response to 1L BR (n = 590; median EFS, 62.7 vs 31.1 months [P< .001]; median OS, 136.1 vs 75.3 months [P< .001]), but the analysis among those who achieved a partial response to 1L BR was limited by the small sample size. These results provide additional evidence for the survival benefit of rituximab maintenance after BR in MCL and support its use in clinical trial design and routine practice.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wang Y, Larson MC, Hwang SR, et al. Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma. Blood Adv. 2026. PMID: 41380101. doi:10.1182/bloodadvances.2025018527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。